Key Action Statement Profile: KAS 6A
| Aggregate evidence quality | Grade B |
| Benefits | Reduced frequency of AOM attributable to vaccine serotypes. Reduced risk of serious pneumococcal systemic disease. |
| Risks, harms, cost | Potential vaccine side effects. Cost of vaccine. |
| Benefits-harms assessment | Preponderance of benefit. |
| Value judgments | Potential vaccine adverse effects are minimal. |
| Intentional vagueness | None. |
| Role of patient preferences | Some parents may choose to refuse the vaccine. |
| Exclusions | Severe allergic reaction (eg, anaphylaxis) to any component of pneumococcal vaccine or any diphtheria toxoid-containing vaccine. |
| Strength | Strong Recommendation |
| Aggregate evidence quality | Grade B |
| Benefits | Reduced frequency of AOM attributable to vaccine serotypes. Reduced risk of serious pneumococcal systemic disease. |
| Risks, harms, cost | Potential vaccine side effects. Cost of vaccine. |
| Benefits-harms assessment | Preponderance of benefit. |
| Value judgments | Potential vaccine adverse effects are minimal. |
| Intentional vagueness | None. |
| Role of patient preferences | Some parents may choose to refuse the vaccine. |
| Exclusions | Severe allergic reaction (eg, anaphylaxis) to any component of pneumococcal vaccine or any diphtheria toxoid-containing vaccine. |
| Strength | Strong Recommendation |